melphalan and Adenocarcinoma--Papillary

Antitumor efficiencies of cytostatics dioxadet, cisplatin, mitomycin C, melphalan, and paclitaxel after a single intraperitoneal or intravenous injection in doses of 1.5, 4, 1.5, 2, and 5 mg/kg, respectively, were studied on the model of transplanted ovarian tumor in 124 rats. The antitumor effects were evaluated by the increase in median survival. Dioxadet, cisplatin, and melphalan injected intraperitoneally significantly prolonged the lifespan median - by 79, 88, and 114%, respectively, and were in fact ineffective, when injected intravenously. Intraperitoneal mitomycin C prolonged lifespan median by just 35%, intravenous - by 152%. Paclitaxel injected intraperitoneally and intravenously prolonged the lifespan median by 45 and 81%, respectively.

Topics: Adenocarcinoma, Papillary; Animals; Antineoplastic Agents; Ascites; Cisplatin; Female; Injections, Intraperitoneal; Injections, Intravenous; Melphalan; Mitomycin; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Rats; Survival Analysis; Treatment Outcome; Triazines

A patient with ovarian carcinoma who subsequently developed the paraneoplastic syndrome of cerebellar degeneration is presented. The literature is reviewed and possible explanations of the phenomenon are discussed.

Topics: Abdominal Neoplasms; Adenocarcinoma, Papillary; Autopsy; Cerebellar Diseases; Combined Modality Therapy; Female; Humans; Melphalan; Middle Aged; Neurologic Examination; Ovarian Neoplasms; Paraneoplastic Syndromes; Physical Therapy Modalities; Thiamine

Seventy-one cases of primary adenocarcinoma of the fallopian tube treated at The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston were reviewed. The most common presenting symptoms were abdominal pain, abnormal uterine bleeding, and vaginal discharge. The most common physical finding was a palpable abdominal or pelvic mass. The preoperative diagnosis was correct for two patients. Initial therapy consisted of surgery alone, surgery plus radiation therapy, surgery plus chemotherapy, and a combination of surgery, chemotherapy, and radiation therapy in 10, 32, 21, and eight cases, respectively. The median survival for patients in these treatment groups was 33, 22, 27, and 22 months, respectively; the median survival for all patients was 23 months. No statistically significant differences emerged among the survival curves of patients treated with each of the above regimens.

Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Melphalan; Middle Aged; Progestins; Time Factors

Ten patients with advanced ovarian carcinoma were treated with hexamethylmelamine and melphalan after failing first-line combination chemotherapy. In eight patients residual disease was evident only at second-look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease to 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second-look operation may improve the salvage of patients with advanced ovarian carcinoma.

Topics: Adenocarcinoma, Papillary; Aged; Altretamine; Drug Therapy, Combination; Female; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Triazines

Topics: Abdominal Neoplasms; Adenocarcinoma, Papillary; Aged; Alkylating Agents; Ascitic Fluid; Chromosomes; Female; Humans; Hydroxyprogesterones; Karyotyping; Melphalan; Methods; Neoplasm Metastasis; Neoplastic Cells, Circulating; Ovarian Neoplasms

Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Cystadenoma; Female; Granulosa Cell Tumor; Humans; Melphalan; Neoplasm Metastasis; Ovarian Neoplasms

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Female; Humans; Melphalan; Middle Aged; Ovarian Neoplasms; Palliative Care